Note: This article does not constitute any investment advice or recommendations; please refer to official/company announcements for authoritative information. This article is intended solely for the introduction of medications related to medical health and does not recommend treatment plans (if involved), nor does it represent the platform's position.Authorization is required for any article reprint.
Recently, a leading domestic enterprise in the field of CAR-T cell therapyFosun Kite Biotechnology Co., Ltd. Completes a New Round of Strategic Financing.This round of financing was jointly completed by Shenye Capital, a subsidiary of Shenzhen Holdings Group, in collaboration with Fosun Health Capital, Pingshan Guidance Fund, and Kunpeng Capital.
The completion of this strategic investment marks the beginning of a new development cycle for the company under its new equity structure. It also represents Shenzhen Holdings Group’s strategic move to align with Shenzhen’s “20+8” industrial cluster deployment, precisely positioning itself in the frontier sector of cell and gene therapy (CGT). Furthermore, it serves as a vivid demonstration of how Shenzhen’s state-owned capital leverages financial linkages to guide the clustering and accelerated rise of the high-end biopharmaceutical industry in Shenzhen, injecting strong momentum into the city’s ambition to build a global CGT industry hub.
Fosun Kite Biotechnology Co., Ltd. is a high-tech biopharmaceutical enterprise controlled by Fosun Pharma. Since its establishment, the company has adhered to the mission of “Focused on Cures, Illuminating Lives,” and is dedicated to the research and development, industrialization, and commercialization of oncology cell therapy products.In June 2021, Fosun Kairos received approval for the market launch of China's first CAR-T cell therapy product—Yikaida.®(Axicabtagene Celoleucel Injection).June 2023, Yikaida®Yikaida Approved for New Indication (Adult Large B-Cell Lymphoma Refractory to First-Line Immunochemotherapy or Relapsing Within 12 Months After First-Line Immunochemotherapy)®The successful market launch officially ushered in the inaugural year of CAR-T therapy in China and continues to lead the high-quality development of lymphoma treatment. Yikaida® has been approved for the treatment of large B-cell lymphoma in second-line or later and third-line or later settings. Currently, bridging clinical trials for a third indication are underway and have been included in the Breakthrough Therapy Designation program.The company's second CAR-T product, brexucabtagene autoleucel injection (code: FKC889)Its marketing application was accepted by the National Medical Products Administration in September 2025, primarily for the treatment of adult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia.In addition to CAR-T, Fosun Kairos is also expanding into other cell therapy areas.In January 2026, the company entered into a strategic partnership with Sibiman Biologics, securing exclusive commercialization rights in mainland China and the Hong Kong and Macao Special Administrative Regions for AlloJoin, the latter’s core product—a stem cell therapy targeting knee osteoarthritis. The pivotal Phase III clinical trial of this drug completed the enrollment of over 500 patients in May 2026, with expectations to submit a New Drug Application (NDA) in 2027.Investors in this round include Shenzhen State-owned Assets Supervision and Administration Commission-affiliated entities such as Shenye Capital, Pingshan Guidance Fund, Kunpeng Capital, and Fosun Pharma’s subsidiary Fuxian Capital. Notably, Shenye Capital had previously joined forces with Pingshan Industrial Investment to establish the “Shenye Xingping Equity Investment Fund” with a total scale of RMB 500 million, focusing on strategic emerging industries such as biopharmaceuticals. This strategic investment in Fosun Kairos marks a key step for Shenye Group in building a comprehensive industrial chain layout in the cell and gene therapy (CGT) sector.Currently, Shenzhen has included cell and gene therapy (CGT) in the key cultivation list for future industries within its “20+8” industrial clusters, introduced the “Ten Cell Therapy Policies” as special supportive measures, and explicitly set a target to exceed RMB 20 billion in the city’s CGT industry scale by 2028. Nearly 200 companies across the industrial chain have already been aggregated in the region. Following its establishment in Pingshan District, Shenzhen, Fosun Kairos will fully leverage its technological barriers and commercial operational advantages to continuously advance the layout of localized R&D centers and regional GMP-compliant production bases, thereby facilitating the localization and implementation of cutting-edge global cell therapy technologies and mature industrialization experience in Shenzhen.Sources: Fosun Kairos, compiled from public information
Scan the QR code to join the groupMastering CAR-T Therapy, Stem Cell Therapy, and GeneTherapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Therapeutics
